ArticleAdvances in therapy2021

Neoadjuvant Therapy with Concurrent Docetaxel, Epirubicin, and Cyclophosphamide (TEC) in High-Risk HER2-Negative Breast Cancers.

Bryan Li et al.PubMed ↗Publisher ↗

No numbers read from the abstract.